Anti-human Cytotoxic T-lymphocyte Associated Protein 4 recombinant monoclonal antibodies
Ipilimumab biosimilar antibodies comprise the variable region of Ipilimumab and either the same constant region of Ipilimumab or a different one with distinct effector functions (ADCC and ADCP).
Ipilimumab which contains a human IgG1 constant region displays high effector functions; the other biosimilar features an IgG1fut or IgG4 (S228P) constant region that exhibits very high or low effector functions, respectively. These non-therapeutic antibodies can be used for the comparative study of the complex interactions induced by their Fc domains.
Key features
- Each lot is functionally tested and validated
- Choice of different isotypes for high/low effector functions
- The complete sequence of the antibody constructs has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
Ipilimumab background
Ipilimumab, a fully human IgG1 monoclonal antibody targets the Cytotoxic T-lymphocyte Associated Protein 4 (CTLA4), also known as CTLA-4 or CD152. CTLA4 is an important immune checkpoint and negative regulator of T cell activation. Upon binding to CTLA-4, Ipilimumab inhibits negative signals that physiologically downregulate T cell activation and exerts its therapeutic activity by upregulating the antitumor activity of T lymphocytes. In addition, Ipilimumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) and TNF-α production. Ipilimumab is FDA-approved for the treatment of unresectable or metastatic melanoma. Ipilimumab is undergoing various clinical trials for other types of cancers, including lung cancer.
Read our product flyer on Clinically relevant monoclonal antibodies
More isotypes are available and can be used for comparison of biological activities such as ADCC
